136.3p 2.8 2.1%
Last Trade - 8:14am
| Market Cap | ÂŁ84.5m |
| Enterprise Value | ÂŁ78.8m |
| Revenue | ÂŁ1.06m |
| Position in Universe | 1068th / 1810 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 30th Jun | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 4.52 | 5.06 | 2.62 | 1.94 | 2.36 | 1.06 | 3.10 | 9.85 | -25.2% | ||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Genedrive Plc is a United Kingdom-based holding company engaged in molecular diagnostics business. The Company provides a molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. Its geographical segments include the United Kingdom, Europe, the United States of America and Asia. Genedrive is a small polymerase chain reaction (PCR) platform, which enables nucleic acid amplification and detection from various sample types, including plasma, sputum and buccal swabs. Genedrive system includes Genedrive hepatitis C virus (HCV) ID Kit for detection of Hepatitis C, and Genedrive IL28B ID Kit for the detection of Interleukin 28B genotyping status.
| Last Annual | June 30th, 2020 |
| Last Interim | June 30th, 2020 |
| Incorporated | February 15, 2007 |
| Public Since | April 4, 2007 |
| No. of Shareholders: | n/a |
| No. of Employees: | 46 |
| Sector | Healthcare |
| Industry | Healthcare Equipment & Supplies |
| Index | FTSE Aim All Share , |
| Exchange | London Stock Exchange (AIM) |
| Shares in Issue | 63,310,048 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 48 Grafton Street, MANCHESTER, M13 9XX, United Kingdom |
| Web | http://www.genedriveplc.com/ |
| Phone | +44 161 9890245 |
| Contact | Paul McManus (Financial PR and Investor Relations) |
| Auditors | PricewaterhouseCoopers LLP |
As of 8:14am, shares in Genedrive are trading at 136.3p, giving the company a market capitalisation of ÂŁ84.5m. This share price information is delayed by 15 minutes.
Shares in Genedrive are currently trading at 136.3p and the price has moved by 1.38k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Genedrive price has moved by 1.21k% over the past year.
Of the analysts with advisory recommendations for Genedrive, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Genedrive is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Genedrive is scheduled to issue upcoming financial results on the following dates:
Genedrive does not currently pay a dividend.
Genedrive does not currently pay a dividend.
Genedrive does not currently pay a dividend.
To buy shares in Genedrive you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Genedrive are currently trading at 136.3p, giving the company a market capitalisation of ÂŁ84.5m.
Here are the trading details for Genedrive:
Based on an overall assessment of its quality, value and momentum, Genedrive is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Genedrive are currently priced at 136.3p. At that level they are trading at 68.54% premium to the analyst consensus target price of 80.87.
Analysts covering Genedrive currently have a consensus Earnings Per Share (EPS) forecast of -0.093 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Genedrive. Over the past six months, the relative strength of its shares against the market has been 31.9%. At the current price of 136.3p, shares in Genedrive are trading at 42.6% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Genedrive.
Genedrive's management team is headed by:
Here are the top five shareholders of Genedrive based on the size of their shareholding:
